Evidence map›Paper›PMID 39976482›Full record

ArticleEmerging microbes & infections2025

Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinib.

André Schreiber, Nicole Oberberg, Benjamin Ambrosy, Franziska Rodner, Sriram Kumar, Duygu Merve Caliskan, Linda Brunotte, Martin Beer, Stephan Ludwig

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

André SchreiberInstitute of Virology Muenster, University of Muenster, Muenster, Germany.ORCID 0000-0002-0362-8894
Nicole OberbergInstitute of Virology Muenster, University of Muenster, Muenster, Germany.ORCID 0009-0008-9126-4429
Benjamin AmbrosyInstitute of Virology Muenster, University of Muenster, Muenster, Germany.ORCID 0000-0001-8882-5143
Franziska RodnerInstitute of Virology Muenster, University of Muenster, Muenster, Germany.ORCID 0000-0002-4996-7816
Sriram KumarInstitute of Virology Muenster, University of Muenster, Muenster, Germany.ORCID 0000-0001-6464-1219
Duygu Merve CaliskanInstitute of Virology Muenster, University of Muenster, Muenster, Germany.ORCID 0000-0002-8064-9146
Linda BrunotteInstitute of Virology Muenster, University of Muenster, Muenster, Germany.ORCID 0000-0001-8074-7400
Martin BeerInstitute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
Stephan LudwigInstitute of Virology Muenster, University of Muenster, Muenster, Germany.ORCID 0000-0003-4490-3052

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highly pathogenic avian influenza A viruses (HPAIV) pose a significant threat to both animal and human health. These viruses have the potential to cause severe respiratory and systemic infections in birds and several mammalian species. The recent global outbreak of the H5N1 clade 2.3.4.4b spread in wild and domestic birds is now considered to be a panzoonosis. Spillover events in dairy cattle farms in the U.S. have highlighted the urgent need for effective antiviral therapies, especially in view of human infections. This study investigates the selective MEK1/2 inhibitor zapnometinib (ZMN) as a potential antiviral agent against HPAIVs. Our

Indexed as

Antiviral AgentsInfluenza A virusInfluenza A Virus, H5N1 SubtypeMAP Kinase Kinase 1MAP Kinase Kinase 2Protein Kinase InhibitorsAnimalsCell LineDogsEpithelial CellsHumansIndolesInfluenza, HumanPhenolsVirus Replication5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinoneAntiviral AgentsIndolesMAP Kinase Kinase 1MAP Kinase Kinase 2PhenolsProtein Kinase Inhibitorsantiviral drug treatmentHPAIVMEK1/2 inhibitionRaf/MEK/ERK signalling pathwayZapnometinib

Identifiers

PMID39976482
PMCPMC11915740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.